News

Orphan drug designation provides a seven-year term of market exclusivity for IPF upon final FDA approval. Orphan drug designation would position NeoPharm to be able to take advantage

Laxai said that the acquisition has been completed for $3.6m consisting of $1.5mm in cash, $0.75mm in notes, $0.60mm in assumed liabilities, and 5.6mm common shares of Laxai

The company claimed that the new outpatient dosing option provides physicians and patients with the flexibility of a dosing regimen with a reduced infusion time. The new regimen

The patent entitled ‘Sustained-Release Bupropion and Bupropion/Mecamylamine Tablets’ discloses the formulation of pharmaceutical tablets containing sustained-release granules of Bupropion HCl distributed in a sustained-release matrix. The patent will

Prialt, a non-opioid analgesics, works by targeting and blocking N-type calcium channels on nerves in the spinal cord that ordinarily transmit pain signals. It has been evaluated as

According to the agreement, Amgen will run an additional Kineret campaign at its facility in Boulder lity in Colorado, and also manufacture the drug at its Puerto Rico

The agreement includes a requirement for Stason to purchase a minimum of one million units of the Unitract 1mL syringe per year during the term of the contract

As part of the agreement, Astimex is expected to cover distribution of Asonor in Sweden and Finland by the mid of year 2010. Asonor has its presence in

The new facility will deliver an additional 300 million treatments of albendazole per year. The global programme to eliminate LF began in 2000, under which more than 1.9